Skip to main content
Irritable Bowel SyndromeGut healthDrugPhase 2

What this study is

The purpose of this study is to evaluate how well brenipatide (LY3537031) is tolerated what side effects may occur, and the safety and efficacy in participants with Irritable Bowel Syndrome-Constipation (IBS-C). The study drug will be administered subcutaneously (SC) (under the skin) when compared with placebo.

The study will last approximately 36 weeks.

What's being tested

  • LY3537031

    Intervention · DRUG

  • Placebo

    Intervention · DRUG

Both interventions

Administered SC.

Study details

Official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Brenipatide in the Treatment of Adult Participants With IBS-C
Sponsor
Eli Lilly and Company
Conditions
Irritable Bowel Syndrome · Constipation
Enrolling
342 people
Starts
2026-04-29
Est. completion
2027-09
Design
Double-blind, randomized, parallel groups, Phase 2
Record
View on ClinicalTrials.gov ↗